Exelixis (NASDAQ:EXEL – Get Free Report)‘s stock had its “market outperform” rating reiterated by JMP Securities in a note issued to investors on Wednesday, Benzinga reports. They currently have a $27.00 target price on the biotechnology company’s stock. JMP Securities’ target price indicates a potential upside of 14.55% from the stock’s current price. Several other […]
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) Director Alan M. Garber sold 19,205 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the sale, the director now owns 35,703 shares […]
Assenagon Asset Management S.A. lessened its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.9% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,949,443 shares of the biotechnology company’s stock after selling 368,961 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Exelixis were worth $46,767,000 as of its most recent […]
Assenagon Asset Management S.A. cut its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 15.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,949,443 shares of the biotechnology company’s stock after selling 368,961 shares during the quarter. Assenagon […]
Trexquant Investment LP lifted its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 94.9% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 451,034 shares of the biotechnology company’s stock after buying an additional 219,567 shares during the period. Trexquant Investment LP owned […]